Characteristics of adult African-American participants in the CSSCD with SCA who completed lung function testing
| . | Adult with SCA (n = 430)* . | Adult with SCA who lived until end of follow-up (n = 367) . | Adult with SCA who died during follow-up (n = 63) . | P (survival vs death)† . |
|---|---|---|---|---|
| Demographic and clinical characteristics | ||||
| Age at PFT (years) | 32.6 ± 9.5‡ | 32.4 ± 9.4 | 33.4 ± 10.4 | .439 |
| Males (%) | 41.2 | 37.9 | 60.3 | .001 |
| Body mass index (kg/m2) | 21.5 ± 3.7 | 21.6 ± 3.7 | 20.9 ± 3.8 | .174 |
| ACS event, post-PFT (%) | 15.1 | 14.2 | 20.6 | .186 |
| ACS rate (events/patient-y), post-PFT | 0.04 ± 0.15 | 0.03 ± 0.10 | 0.11 ± 0.30 | .097§ |
| Pain event, post-PFT (%) | 33.0 | 31.9 | 39.7 | .224 |
| Pain rate (events/patient-y), post-PFT | 0.53 ± 1.34 | 0.43 ± 1.08 | 1.12 ± 2.28 | .078§ |
| Asthma (%) (n = 374) | 4.5 | 3.3 | 13.6 | .009 |
| History of chronic transfusion (%) | 12.6 | 11.4 | 19.0 | .092 |
| Smoking at or near time of PFT (%)(n = 429) | 35.0 | 33.3 | 44.4 | .088 |
| Laboratory characteristics | ||||
| White blood cell count (109/L) (n = 426) | 11.6 ± 2.5 | 11.5 ± 2.4 | 12.4 ± 2.9 | .010 |
| Fetal hemoglobin (g/dL) (n = 416) | 5.7 ± 4.1 | 5.9 ± 4.1 | 4.5 ± 3.7 | .010 |
| Hemoglobin (g/dL) (n = 427) | 8.6 ± 1.2 | 8.7 ± 1.2 | 8.3 ± 1.4 | .013 |
| Platelet count (109/L) (n = 422) | 419.9 ± 114.5 | 419·0 ± 110.4 | 425.2 ± 137.2 | .695 |
| Hematocrit (%) (n = 428) | 25.3 ± 3.7 | 25.4 ± 3.6 | 24.3 ± 4.2 | .037 |
| History of renal insufficiency (%) | 3.7 | 2.7 | 9.5 | .019 |
| Bilirubin (mg/dL) (n = 427) | 3.3 ± 2.0 | 3.3 ± 2.0 | 3.4 ± 2.0 | .699 |
| Lactic dehydrogenase (mg/dL) (n = 417) | 477.4 ± 174.0 | 468.5 ± 169.0 | 529.5 ± 193.9 | .011 |
| Pulmonary function characteristics | ||||
| FEV1% predicted (n = 427) | 77.4 ± 14.1 | 78.3 ± 13.6 | 72.3 ± 16.1 | .002 |
| FEV1% predicted tertile | .017 | |||
| FEV1% predicted <71.1 (%) (n = 140) | 32.8 | 30.1 | 48.4 | |
| 71.1 ≤FEV1% predicted <84.1 (%) (n = 146) | 34.2 | 35.3 | 27.4 | |
| FEV1% predicted ≥84.1 (%) (n = 141) | 33.0 | 34.5 | 24.2 | |
| % predicted FEV1/FVC (n = 427) | 98.1 ± 8.7 | 98.1 ± 8.6 | 97.6 ± 9.2 | .618 |
| % predicted TLC (n = 384) | 83.7 ± 17.5 | 84.0 ± 17.2 | 81.8 ± 19.5 | .373 |
| Ventilatory defect (modified from Pellegrino) (n = 406) | .241 | |||
| Normal pattern (%) (n = 189) | 46.6 | 48.7 | 33.9 | |
| Obstructive pattern (%) (n = 34) | 8.4 | 8.4 | 8.5 | |
| Restrictive pattern (%) (n = 119) | 29.3 | 27.4 | 40.7 | |
| Mixed pattern (%) (n = 6) | 1.5 | 1.4 | 1.7 | |
| Nonspecific pattern (%) (n = 58) | 14.3 | 14.1 | 15.3 |
| . | Adult with SCA (n = 430)* . | Adult with SCA who lived until end of follow-up (n = 367) . | Adult with SCA who died during follow-up (n = 63) . | P (survival vs death)† . |
|---|---|---|---|---|
| Demographic and clinical characteristics | ||||
| Age at PFT (years) | 32.6 ± 9.5‡ | 32.4 ± 9.4 | 33.4 ± 10.4 | .439 |
| Males (%) | 41.2 | 37.9 | 60.3 | .001 |
| Body mass index (kg/m2) | 21.5 ± 3.7 | 21.6 ± 3.7 | 20.9 ± 3.8 | .174 |
| ACS event, post-PFT (%) | 15.1 | 14.2 | 20.6 | .186 |
| ACS rate (events/patient-y), post-PFT | 0.04 ± 0.15 | 0.03 ± 0.10 | 0.11 ± 0.30 | .097§ |
| Pain event, post-PFT (%) | 33.0 | 31.9 | 39.7 | .224 |
| Pain rate (events/patient-y), post-PFT | 0.53 ± 1.34 | 0.43 ± 1.08 | 1.12 ± 2.28 | .078§ |
| Asthma (%) (n = 374) | 4.5 | 3.3 | 13.6 | .009 |
| History of chronic transfusion (%) | 12.6 | 11.4 | 19.0 | .092 |
| Smoking at or near time of PFT (%)(n = 429) | 35.0 | 33.3 | 44.4 | .088 |
| Laboratory characteristics | ||||
| White blood cell count (109/L) (n = 426) | 11.6 ± 2.5 | 11.5 ± 2.4 | 12.4 ± 2.9 | .010 |
| Fetal hemoglobin (g/dL) (n = 416) | 5.7 ± 4.1 | 5.9 ± 4.1 | 4.5 ± 3.7 | .010 |
| Hemoglobin (g/dL) (n = 427) | 8.6 ± 1.2 | 8.7 ± 1.2 | 8.3 ± 1.4 | .013 |
| Platelet count (109/L) (n = 422) | 419.9 ± 114.5 | 419·0 ± 110.4 | 425.2 ± 137.2 | .695 |
| Hematocrit (%) (n = 428) | 25.3 ± 3.7 | 25.4 ± 3.6 | 24.3 ± 4.2 | .037 |
| History of renal insufficiency (%) | 3.7 | 2.7 | 9.5 | .019 |
| Bilirubin (mg/dL) (n = 427) | 3.3 ± 2.0 | 3.3 ± 2.0 | 3.4 ± 2.0 | .699 |
| Lactic dehydrogenase (mg/dL) (n = 417) | 477.4 ± 174.0 | 468.5 ± 169.0 | 529.5 ± 193.9 | .011 |
| Pulmonary function characteristics | ||||
| FEV1% predicted (n = 427) | 77.4 ± 14.1 | 78.3 ± 13.6 | 72.3 ± 16.1 | .002 |
| FEV1% predicted tertile | .017 | |||
| FEV1% predicted <71.1 (%) (n = 140) | 32.8 | 30.1 | 48.4 | |
| 71.1 ≤FEV1% predicted <84.1 (%) (n = 146) | 34.2 | 35.3 | 27.4 | |
| FEV1% predicted ≥84.1 (%) (n = 141) | 33.0 | 34.5 | 24.2 | |
| % predicted FEV1/FVC (n = 427) | 98.1 ± 8.7 | 98.1 ± 8.6 | 97.6 ± 9.2 | .618 |
| % predicted TLC (n = 384) | 83.7 ± 17.5 | 84.0 ± 17.2 | 81.8 ± 19.5 | .373 |
| Ventilatory defect (modified from Pellegrino) (n = 406) | .241 | |||
| Normal pattern (%) (n = 189) | 46.6 | 48.7 | 33.9 | |
| Obstructive pattern (%) (n = 34) | 8.4 | 8.4 | 8.5 | |
| Restrictive pattern (%) (n = 119) | 29.3 | 27.4 | 40.7 | |
| Mixed pattern (%) (n = 6) | 1.5 | 1.4 | 1.7 | |
| Nonspecific pattern (%) (n = 58) | 14.3 | 14.1 | 15.3 |